Sorrento Therapeutics Inc
NASDAQ:SRNE
Sorrento Therapeutics Inc
Other Operating Expenses
Sorrento Therapeutics Inc
Other Operating Expenses Peer Comparison
Competitive Other Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Company | Other Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sorrento Therapeutics Inc
NASDAQ:SRNE
|
Other Operating Expenses
$75.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Other Operating Expenses
$169m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Operating Expenses
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Operating Expenses
-$791m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-7%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Operating Expenses
$49.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Operating Expenses
-$13.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Sorrento Therapeutics Inc's Other Operating Expenses?
Other Operating Expenses
75.4m
USD
Based on the financial report for Dec 31, 2022, Sorrento Therapeutics Inc's Other Operating Expenses amounts to 75.4m USD.